Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Nnat is a brain-specific, highly conserved new gene related to mammalian development. Neuronation (Nnat) is a brain-specific imprinted gene originally cloned from brain in 1996. The human Nnat gene is 3973 bp in length and contains 3 exons and 2 introns. Nnat mRNA has two splicing forms: α and β, both of which have open reading frames in uniform phase, encoding 81 and 54 amino acids, respectively. The difference is that the second exon of β form is cut off.
Figure 1. Schematic representation of the relationship between neuronatin (Nnat) and glucose-induced endoplasmic reticulum (ER) stress in pancreatic b-cells. (Asahara, S. I, et al. 2018)
Nnat Expression
Using Northern blot analysis, it was found that Nnat was selectively expressed in the brain of newborn rats, but not expressed in three tissues such as heart, kidney, and liver. It first appeared in the middle stage of the embryo, at which time the neural tube was closed and neuroepithelial cells began to proliferate. At the peak of neural development at 16 to 19 days, Nnat mRNA expression was significantly enhanced. As the development of the nervous system is completed, its expression declines to the expression level of the adult brain. The transmembrane protein encoded by Nnat may act as a protein ligand, helper, smaller cell adhesion molecule, etc., and participate in the signal of the maturation of the nervous system, development or differentiation of the hindbrain and anterior pituitary.
Subtractive hybridization also confirmed that mouse Nnat expression was down-regulated in P19 embryonic cancer cells, and transiently expressed in rhizomes 3 and 5 of the early hindbrain development and the bottom of the foregut pocket. In the later stage of embryogenesis, the Nnat gene is strongly expressed in the central and peripheral nervous systems. These results indicate that Nnat is involved in the maturation or maintenance of segment identity and nervous system structure during the development of the hindbrain and pituitary. Studies have found that nerve growth factor (NGF) can cause PC12 cell proliferation to stop and transform into a neuronal phenotype, while Nnat mRNA expression is down-regulated. After NGF was removed, Nnat mRNA expression returned to background levels. The role of NGF does not depend on protein and RNA synthesis. Of the two splice forms, only the alpha form is expressed in PC12 cells. In addition, in thyrotropic tumor treated with thyroid hormone, up-regulation of Nnat mRNA expression was also observed.
NNAT and Disease
The expression of two splicing forms of Nnat α and β was detected in three of the four lipoma samples. The gene expression was also detected in tumor cell lines, but not in cultured fibroblasts and adipose tissue. The presence of transcription of Nnat in tumor studies suggests the neural origin of these tumor cells. Similarly, strong expression of Nnat was observed in several patients with pituitary adenomas. However, Nnat mRNA expression was up-regulated in thyroid-stimulating tumors treated with thyroid hormones. Subtractive hybridization analysis demonstrated that Nnat mRNA was present in cell lines expressing thyroid-stimulating hormone, but not in progenitor cell lines expressing alpha subunits. The result may be a calcium-dependent thyroid-stimulating signal transduction pathway.
Studies have shown that the unmethylated Nnat allele is completely missing in the region where the human Nnat gene is located, in leukemia cell lines, and in 20 samples (29 total) of acute myeloid lymphoid leukemia. Through methylation analysis, it was found that Nnat mRNA showed normal methylation in normal hematopoietic progenitor cells and leukemia cells, but gene expression could not be detected in hypermethylated leukemia cells. After demethylation of hypermethylated leukemia cells by treatment with 5'-aza-2'-edoxy cytidine, with the recovery of the normal methylation pattern of the gene, the expression of Nnat was again activated. These results indicate that hypermethylation of the Nnat locus is a common event in children with acute myeloid and lymphoid leukemia. The abnormal methylation of the Nnat locus is the result of 20q11.2 to q12 gene regulation disorders in leukemias.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.